SEC Form SC 13G/A filed by Myomo Inc. (Amendment)

$MYO
Industrial Specialties
Health Care
Get the next $MYO alert in real time by email
SC 13G/A 1 rosalind_myo_13ga4_apr25.htm Schedule 13G

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 4)

 

Under the Securities Exchange Act of 1934

Myomo, Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

62857J201

(CUSIP Number)

March 31, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨  Rule 13d-1(b)
x  Rule 13d-1(c)
¨  Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


 

NYC#: 139632.2


 


 

 

 

 

 

 

CUSIP No. 62857J201

 

13G/A

 

Page 2 of 8 Pages

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Rosalind Advisors, Inc.

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
ONTARIO, CANADA

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER  
 
0

 

6.

 

SHARED VOTING POWER
 
2,447,740 shares of Common Stock

4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

7.

 

SOLE DISPOSITIVE POWER
 
0

 

8.

 

SHARED DISPOSITIVE POWER
 
2,447,740 shares of Common Stock

4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,447,740 shares of Common Stock

4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.9% above1

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

CO

 

 

 

 

 

 

 


1 The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 28,487,168 shares of the Issuer’s common stock outstanding as of March 1, 2024, in accordance with Issuer’s 10-K filed on March 8, 2024. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

  


 

NYC#: 139632.2


 


CUSIP No. 62857J201

 

13G/A

 

Page 3 of 8 Pages

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Steven Salamon

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
ONTARIO, CANADA

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER
 
0

 

6.

 

SHARED VOTING POWER
 
2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

7.

 

SOLE DISPOSITIVE POWER
 
0

 

8.

 

SHARED DISPOSITIVE POWER
 
2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.9% above

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

IN

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Gil Aharon

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
ONTARIO, CANADA

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER
 
0

 

6.

 

SHARED VOTING POWER
 
 2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

7.

 

SOLE DISPOSITIVE POWER
 
0

 

8.

 

SHARED DISPOSITIVE POWER
 
 2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.9% above

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

IN

 

 

 

 

 

 

 

 

CUSIP No. 62857J201

 

13G/A

 

Page 4 of 8 Pages

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Rosalind Master Fund L.P.

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
CAYMAN ISLANDS

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER
 
0

 

6.

 

SHARED VOTING POWER
 
2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

7.

 

SOLE DISPOSITIVE POWER
 
0

 

8.

 

SHARED DISPOSITIVE POWER
 
2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,447,740 shares of Common Stock

 4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.9% above

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

PN

 

 

 

 

 

 

 

 

 

 

 

 


 

NYC#: 139632.2


 


 

 

 

 

 

 

CUSIP No. 62857J201

 

13G/A

 

Page 5 of 8 Pages

 

 

 

 

 

Item 1.

 

(a)

Name of Issuer: Myomo, Inc.

 

 

 

 

(b)

Address of Issuer’s Principal Executive Offices
137 Portland St., 4th Floor, Boston, Massachusetts

 

 

 

Item 2.

 

(a)

Name of Person Filing

Rosalind Advisors, Inc. (“Advisor” to RMF)

Rosalind Master Fund L.P. (“RMF”)

Steven Salamon (“President”)

Steven Salamon is the portfolio manager of the Advisor which advises RMF.

 

 

 

 

(b)

Address of the Principal Office or, if none, residence
Rosalind Advisors, Inc.

15 Wellesley Street West,

Suite 326

Toronto, Ontario

M4Y 0G7 Canada

 

Rosalind Master Fund L.P.

P.O. Box 309

Ugland House, Grand Cayman

KY1-1104, Cayman Islands

 

Steven Salamon

15 Wellesley Street West,

Suite 326

Toronto, Ontario

M4Y 0G7 Canada

 

Gilad Aharon

15 Wellesley Street West,

Suite 326

Toronto, Ontario

M4Y 0G7 Canada

 

 

 

 

 

(c)

Citizenship
Rosalind Advisors, Inc.: Ontario, Canada

Rosalind Master Fund L.P.: Cayman Islands

Steven Salamon: Ontario, Canada

Gilad Aharon: Ontario, Canada

 

 

 

 

(d)

Title of Class of Securities
Common Stock

 

 

 

 

(e)

CUSIP Number
62857J201


 

NYC#: 139632.2


 


 

 

 

 

 

CUSIP No. 62857J201

 

13G/A

 

Page 6 of 8 Pages

 

 

 

 

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

¨

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

 

 

 

 

(b)

¨

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

 

 

 

 

(c)

¨

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

 

 

 

 

(d)

¨

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

 

 

 

 

(e)

¨

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

 

 

 

 

(f)

¨

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

 

 

 

 

(g)

¨

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

 

 

 

 

(h)

¨

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

 

 

 

 

(i)

¨

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

 

 

 

 

(j)

¨

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

 

 

 

Item 4.  Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

 

 

 

 

 

(a)

 

Amount beneficially owned:  

 

The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 12 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 26,516,203 shares of the Issuer’s common stock outstanding as of November 02, 2023, in accordance with Issuer’s 10-Q filed on November 07, 2023.

Rosalind Master Fund L.P. may have been deemed to have the beneficial ownership of 2,447,740 shares of common stock representing the beneficial ownership of approximately 9.2% of the common stocks as mentioned above, which excludes the 4,575,385 shares issuable upon the exercise of pre-funded warrants because they contain a blocker provision under which the holder thereof does not have the right to exercise any of the warrant to the extent that such exercise would result in beneficial ownership by the holder in excess of 9.99% of the Common Stock. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of the warrants due to the Blockers.

Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.  Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.

 

 

 

 

 

 

(b)

 

Percent of class:  

Rosalind Advisors, Inc. – 9.9% above

Rosalind Master Fund L.P. – 9.9% above

Steven Salamon – 9.9% above

Gilad Aharon – 9.9% above

 

 

 

 

 

 


 

NYC#: 139632.2


 


 

 

 

 

 

CUSIP No. 62857J201

 

13G/A

 

Page 7 of 8 Pages

 

 

 

 

 

 

(c)

 

Number of shares as to which the person has:  

 

 

 

(i)

Shared power to vote or to direct the vote  

Rosalind Advisors, Inc. –  2,447,740 shares of Common Stock

Rosalind Master Fund L.P. –  2,447,740 shares of Common Stock

Steven Salamon – 2,447,740 shares of Common Stock

Gilad Aharon - 2,447,740 shares of Common Stock

 

 

 

 

 

 

 

 

 

(ii)

Sole power to dispose or to direct the disposition of  – 0

 

 

 

 

 

 

 

 

(iii)

Shared power to dispose or to direct the disposition of  

Rosalind Advisors, Inc. –  2,447,740 shares of Common Stock

Rosalind Master Fund L.P. – 2,447,740 shares of Common Stock

Steven Salamon –  2,447,740 shares of Common Stock

Gilad Aharon - 2,447,740 shares of Common Stock

 

 

 

 

 

 

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5.  Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     o.

Instruction. Dissolution of a group requires a response to this item.

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

Item 7 – 9.  Not Applicable


 

NYC#: 139632.2


 


 

 

 

 

 

CUSIP No. 62857J201

 

13G/A

 

Page 8 of 8 Pages

 

 

 

 

 

Item 10.  Certification.

 

 

 

 

 

 

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

04/25/2024

Date

 

 

Signature

 

Steven Salamon/President Rosalind Advisors, Inc.

Name/Title

 

 

Exhibit A

Joint Filing Agreement

 

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them.

 

 

Rosalind Advisors, Inc.

By: _____________________________

Name: Steven Salamon

Title: President

 

Rosalind Master Fund L.P.

By: _____________________________

Name: Mike McDonald

Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

 

By: _____________________________

Name: Steven Salamon


 

NYC#: 139632.2

Get the next $MYO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MYO

DatePrice TargetRatingAnalyst
7/31/2024$7.00Buy
Craig Hallum
5/20/2024$7.00Buy
Lake Street
12/15/2023$6.50Buy
H.C. Wainwright
More analyst ratings

$MYO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

    Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of

    $MYO
    Industrial Specialties
    Health Care
  • Myomo to Report Fourth Quarter 2024 Financial Results on March 10

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on March 10, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate

    $MYO
    Industrial Specialties
    Health Care
  • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

$MYO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MYO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MYO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MYO
SEC Filings

See more

$MYO
Leadership Updates

Live Leadership Updates

See more
  • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Myomo Appoints Heather Getz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

    $BFLY
    $MYO
    Medical Electronics
    Health Care
    Industrial Specialties
  • Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

    $MYO
    Industrial Specialties
    Health Care

$MYO
Financials

Live finance-specific insights

See more
  • Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

    Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of

    $MYO
    Industrial Specialties
    Health Care
  • Myomo to Report Fourth Quarter 2024 Financial Results on March 10

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on March 10, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate

    $MYO
    Industrial Specialties
    Health Care
  • Myomo Reports Record Third Quarter Financial and Operating Results

    $9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Pro

    $MYO
    Industrial Specialties
    Health Care

$MYO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more